Optomed and Toku Inc. enter a partnership to commercialize AI for cardiovascular disease risk

Optomed, a leading manufacturer of handheld fundus cameras and screening software, has signed a global partnership agreement with US-based artificial intelligence company, Toku Inc. The partnership aims to commercialize Toku’s CLAiR and BioAge with Optomed’s AI solution platform globally.

Toku specializes in imaging technology and AI. The company recently received the FDA’s Breakthrough Device designation for its cardiovascular risk detection algorithm, CLAiR. According to MDR, CLAiR has also achieved a CE designation and a UKCA. Toku also has an AI software called BioAge that assesses a person’s biological age compared to their chronological age, which is being commercialized in the United States and globally.

Optomed’s CEO, Juho Himberg comments: “We are excited to partner with Toku and see that this partnership aligns well with Optomed’s strategy to become a leading provider of AI-enabled healthcare solutions. Cardiovascular disease (CVD) is the leading cause of death worldwide, with 49,000 deaths per day globally. To be able to assess the risk for developing CVD early on brings immense benefits to patients and the healthcare system as a whole.”

Toku’s CEO, Ehsan Vagheri adds: “We are thrilled to enter this partnership with Optomed. Toku’s mission is to make identifying diseases accessible for everyone, everywhere, all the time We see great value in making our technology available with a handheld fundus camera that does not require extra space at the clinic and allows mobile or at-home use.”

Contact person

Juho Himberg

CEO, Optomed Plc


Source: Optomed